Woodline Partners LP Fate Therapeutics Inc Transaction History

Woodline Partners LP

$11 Billion
Q3 2024

A detailed history of Woodline Partners LP transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Woodline Partners LP holds 3,065,747 shares of FATE stock, worth $6.81 Million. This represents 0.1% of its overall portfolio holdings.

Number of Shares

3,065,747

Previous 1,002,002 205.96%

Holding current value

$6.81 Million

Previous $3.29 Million 226.54%

% of portfolio

0.1%

Previous 0.03%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$3.12 - $5.57 $6.44 Million - $11.5 Million	2,063,745 Added 205.96%	3,065,747 $10.7 Million
Q2 2024 Aug 14, 2024	SELL	$3.26 - $7.08 $2.9 Million - $6.3 Million	-890,000 Reduced 47.04%	1,002,002 $3.29 Million
Q1 2024 May 15, 2024	BUY	$3.54 - $8.35 $5.33 Million - $12.6 Million	1,506,638 Added 390.96%	1,892,002 $13.9 Million
Q4 2023 Feb 14, 2024	BUY	$1.65 - $3.94 $635,850 - $1.52 Million	385,364 New	385,364 $1.44 Million
Q2 2023 Aug 14, 2023	BUY	$4.76 - $6.59 $247 - $342	52 Added 0.05%	100,056 $476,000
Q1 2023 May 15, 2023	SELL	$4.24 - $11.12 $257,427 - $675,139	-60,714 Reduced 37.78%	100,004 $570,000
Q1 2022 May 16, 2022	SELL	$29.67 - $60.28 $1.14 Million - $2.31 Million	-38,358 Reduced 19.27%	160,718 $6.23 Million
Q4 2021 Feb 14, 2022	BUY	$47.84 - $64.34 $2.21 Million - $2.97 Million	46,119 Added 30.15%	199,076 $11.6 Million
Q3 2021 Nov 15, 2021	BUY	$59.27 - $95.73 $1.3 Million - $2.09 Million	21,851 Added 16.67%	152,957 $9.07 Million
Q2 2021 Aug 16, 2021	BUY	$67.25 - $92.52 $319,168 - $439,099	4,746 Added 3.76%	131,106 $11.4 Million
Q1 2021 May 17, 2021	BUY	$72.16 - $117.4 $9.12 Million - $14.8 Million	126,360 New	126,360 $10.4 Million

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $215M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.

Account

Woodline Partners LP Fate Therapeutics Inc Transaction History